Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04IIU
|
|||
| Former ID |
DNC004666
|
|||
| Drug Name |
INDISULAM
|
|||
| Synonyms |
Indisulam; 165668-41-7; E7070; N-(3-chloro-1H-indol-7-yl)benzene-1,4-disulfonamide; UNII-WJ98J3NM90; E-7070; E 7070; N-(3-Chloro-1H-indol-7-yl)-1,4-benzenedisulfonamide; CHEMBL77517; WJ98J3NM90; N1-(3-chloro-1H-indol-7-yl)benzene-1,4-disulfonamide; 1,4-Benzenedisulfonamide, N-(3-chloro-1H-indol-7-yl)-; ER-35744; N-(3-Chloro-1H-indol-7-yl)benzene-1,4disulfonamide; Indisulam (IND); indisulam (e7070); Indisulam (USAN/INN); AC1Q6VCX; AC1L50QL; SCHEMBL91389; N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide; Indisulam [USAN:INN:BAN]
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Lymphoma [ICD-11: 2A80-2A86; ICD-9: 202.8, 208.9] | Phase 2 | [1], [2] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C14H12ClN3O4S2
|
|||
| Canonical SMILES |
C1=CC2=C(C(=C1)NS(=O)(=O)C3=CC=C(C=C3)S(=O)(=O)N)NC=C2Cl
|
|||
| InChI |
1S/C14H12ClN3O4S2/c15-12-8-17-14-11(12)2-1-3-13(14)18-24(21,22)10-6-4-9(5-7-10)23(16,19)20/h1-8,17-18H,(H2,16,19,20)
|
|||
| InChIKey |
SETFNECMODOHTO-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 165668-41-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9372911, 12015040, 14902746, 30420152, 46511460, 47206369, 49879993, 50885085, 53790787, 57399788, 103276735, 103832676, 113461710, 117631365, 126671562, 129225625, 134341871, 135135024, 137094473, 140360685, 165247707, 172821404, 176225599, 178103625, 179294234, 184527860, 198956059, 215780859, 223661106, 226469362, 252215593
|
|||
| ChEBI ID |
CHEBI:145431
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Carbonic anhydrase IX (CA-IX) | Target Info | Modulator | [3], [4] |
| KEGG Pathway | Nitrogen metabolism | |||
| Pathway Interaction Database | HIF-1-alpha transcription factor network | |||
| Reactome | Regulation of gene expression by Hypoxia-inducible Factor | |||
| Reversible hydration of carbon dioxide | ||||
| WikiPathways | Vitamin D Receptor Pathway | |||
| Reversible Hydration of Carbon Dioxide | ||||
| Regulation of Hypoxia-inducible Factor (HIF) by Oxygen | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7046). | |||
| REF 2 | ClinicalTrials.gov (NCT00014625) E7070 in Treating Patients With Stage IV Melanoma. U.S. National Institutes of Health. | |||
| REF 3 | Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-assoc... Bioorg Med Chem Lett. 2004 Jan 5;14(1):217-23. | |||
| REF 4 | Development of small molecule carbonic anhydrase IX inhibitors.BJU Int.2008 Jun;101 Suppl 4:39-40. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.